Wednesday, March 25, 2026
StockstToday.com Logo
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
StocksToday.com Logo
No Result
View All Result
Home AI & Quantum Computing

Palantir Shares Face Steep Decline Amid Valuation Concerns

Robert Sasse by Robert Sasse
November 29, 2025
in AI & Quantum Computing, Analysis, Nasdaq, Tech & Software
0
Palantir Stock
0
SHARES
30
VIEWS
Share on FacebookShare on Twitter

The investment landscape for Palantir Technologies Inc. shifted dramatically in November, as the data analytics firm experienced its most severe monthly decline in over two years. Previously regarded as an unstoppable force in the artificial intelligence sector, the company now finds itself at the center of a heated debate between its chief executive and a prominent hedge fund manager, leaving investors to question whether this represents a buying opportunity or the end of an era.

Strong Fundamentals Clash With Market Sentiment

Paradoxically, Palantir’s operational performance remains robust. The company’s latest quarterly report significantly exceeded Wall Street’s expectations across multiple metrics:
* Revenue surged by 63 percent year-over-year
* Commercial revenue in the United States exploded by 121 percent
* Adjusted earnings per share doubled compared to previous periods

Despite these strong results and an upward revision to annual forecasts, including major contract wins with organizations like PwC UK, investor confidence has been undermined by concerns over the company’s valuation. The situation was further complicated by insider selling activity, with CEO Alex Karp and other executives divesting portions of their holdings during November.

Sector-Wide Rotation Hits AI Stocks

The downturn reflects broader market dynamics rather than company-specific issues alone. November witnessed a significant sector rotation as investors retreated from highly-valued AI securities. Even industry heavyweights including Nvidia and Microsoft saw their share prices retreat during this period.

Market analysts have expressed growing apprehension about valuation levels. Researchers at Jefferies have characterized current pricing as “extreme,” while Deutsche Bank has voiced skepticism about how such astronomical metrics can be justified. With a price-to-earnings ratio that exceeds conventional investment parameters and a Relative Strength Index approaching 79—indicating severely overbought conditions—the risk profile has increased substantially.

Should investors sell immediately? Or is it worth buying Palantir?

High-Profile Clash Highlights Diverging Views

Amid this turbulent backdrop, a public dispute has emerged between Palantir’s leadership and notable investor Michael Burry. The fund manager, who gained fame for his successful bet against the housing market in 2008, has established substantial put options against Palantir with a notional value approaching $1 billion as disclosed in late September.

The response from Palantir’s executive suite was immediate and forceful. Chief Executive Officer Alex Karp used two separate television appearances within a single week to denounce Burry’s position as “completely insane” and implicitly accused him of market manipulation. Burry countered in his latest investment newsletter, arguing that markets have fundamentally misjudged both the lifespan of AI chips and the depreciation cycles affecting major technology firms—a direct challenge to the foundation of the current AI investment boom.

Market Performance and Outlook

Palantir shares concluded recent trading at 145.54 euros, reflecting a decline exceeding 15 percent over a 30-day window. Despite this pullback, the equity maintains a substantial gain of nearly 99 percent since the beginning of the year.

The investment community remains deeply divided. On one side stand impressive operational growth figures and expanding business opportunities. On the other, stretched valuations that permit no margin for error and influential short sellers betting on a substantial correction. Market participants should prepare for continued volatility until the tension between fundamental valuation concerns and AI-driven optimism reaches resolution.

Ad

Palantir Stock: Buy or Sell?! New Palantir Analysis from March 25 delivers the answer:

The latest Palantir figures speak for themselves: Urgent action needed for Palantir investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from March 25.

Palantir: Buy or sell? Read more here...

Tags: Palantir
Robert Sasse

Robert Sasse

About Dr. Robert Sasse Accomplished economist, entrepreneur, and profound expert in financial markets. Dr. Robert Sasse holds a doctorate in economics and combines academic rigor with practical entrepreneurial experience. His deep expertise in economic relationships and unwavering conviction for a free-market liberal economic order drives his mission to provide investors with well-founded knowledge and guidance.
Areas of Expertise:
  • Economic Theory and Practice
  • Free-Market Economics
  • Entrepreneurship and Business Strategy
  • Investment Philosophy
Dr. Sasse's unique combination of academic knowledge and real-world business experience enables him to provide investors with comprehensive insights that bridge theory and practice.

Related Posts

BioNano Genomics Stock
Analysis

BioNano Genomics Stock: A Tale of Operational Gains and Revenue Headwinds

March 25, 2026
Humacyte Stock
Analysis

Humacyte Shares Hit Record Low Amid Capital Raise and Strategic Shifts

March 25, 2026
Evolent Health Stock
AI & Quantum Computing

Evolent Health Bets on AI Leadership Amid Share Price Decline

March 25, 2026
Next Post
Redcare Pharmacy Stock

Redcare Pharmacy Shares Show Signs of Recovery After Steep Decline

Silber Preis Stock

Silver Soars to Unprecedented Heights as Supply Squeeze Intensifies

Figma Stock

Figma Shares Navigate Critical Juncture After Steep Decline

Recommended

Alphabet Stock

Alphabet Shares Face Regulatory Headwinds Despite Autonomous Driving Breakthrough

4 months ago
Dish Network Stock

Institutional Investors Show Diverging Views on Dish Network’s Future

7 months ago
Finance_ Trading ratings today (2)

Lakeland Financial Exceeds Expectations with Fourth Quarter Earnings

2 years ago
DeFi Technologies Stock

DeFi Technologies: Navigating Expansion Amidst Legal Headwinds

3 months ago

Categories

  • AI & Quantum Computing
  • Analysis
  • Analyst Ratings
  • Asian Markets
  • Automotive & E-Mobility
  • Banking & Insurance
  • Bitcoin
  • Blockchain
  • Bonds
  • Breaking News
  • Business & Industry Trends
  • Cannabis
  • Chemicals
  • Commodities
  • Consumer & Luxury
  • Crypto Stocks
  • Cryptocurrency
  • Cyber Security
  • DAX
  • Defense & Aerospace
  • Dividends
  • Dow Jones
  • E-Commerce
  • Earnings
  • Emerging Markets
  • Energy & Oil
  • ETF
  • Ethereum & Altcoins
  • European Markets
  • Forex
  • Gaming & Metaverse
  • Gold & Precious Metals
  • Healthcare
  • Hydrogen
  • Index
  • Industrial
  • Insider Trading
  • IPOs
  • Market Commentary
  • Market News
  • MDAX & SDAX
  • Mergers & Acquisitions
  • Nasdaq
  • Newsletter
  • Penny Stocks
  • Pharma & Biotech
  • Real Estate & REITs
  • Renewable Energy
  • S&P 500
  • Semiconductors
  • Space
  • Stock Picks
  • Stock Targets
  • Stocks
  • TecDAX
  • Tech & Software
  • Telecommunications
  • Trading & Momentum
  • Turnaround
  • Uncategorized
  • Value & Growth

Topics

Adobe Alibaba Alphabet Amazon AMD Apple ASML BioNTech Bitcoin Bloom Energy Broadcom Coinbase D-Wave Quantum Eli Lilly Fiserv IBM Intel Kraft Heinz Marvell Technology META Micron Microsoft MP Materials MSCI World ETF Newmont Mining NIO Novo Nordisk Nvidia Ocugen Oracle Palantir PayPal Plug Power QuantumScape Realty Income Robinhood Rocket Lab USA Salesforce Strategy Synopsys Tesla Tilray Unitedhealth Uranium Energy Viking Therapeutics
No Result
View All Result

Highlights

MongoDB Strengthens Leadership Amid AI-Driven Growth Phase

Talphera Shares Slide as Funding Concerns Overshadow Clinical Progress

Hain Celestial Sheds Snack Division in Strategic Overhaul

Technology Sector Faces Mounting Headwinds as AI Hype Meets Macroeconomic Reality

Lumen’s AI Infrastructure Push Gains Recognition Amid Strategic Overhaul

Microsoft’s AI Ambitions Strain Finances as Cash Reserves Shrink

Trending

BioNano Genomics Stock
Analysis

BioNano Genomics Stock: A Tale of Operational Gains and Revenue Headwinds

by Kennethcix
March 25, 2026
0

BioNano Genomics has wrapped up its fiscal year 2025, presenting a financial picture marked by significant operational...

Humacyte Stock

Humacyte Shares Hit Record Low Amid Capital Raise and Strategic Shifts

March 25, 2026
Evolent Health Stock

Evolent Health Bets on AI Leadership Amid Share Price Decline

March 25, 2026
MongoDB Stock

MongoDB Strengthens Leadership Amid AI-Driven Growth Phase

March 25, 2026
Talphera Stock

Talphera Shares Slide as Funding Concerns Overshadow Clinical Progress

March 25, 2026

StocksToday.com is your one-stop destination for the latest stock news and analysis. We provide in-depth coverage of the stock market, including market news, company news, sector news, IPO news, investment strategies, personal finance, international markets, and more.

Follow us on social media:

Recent News

  • BioNano Genomics Stock: A Tale of Operational Gains and Revenue Headwinds
  • Humacyte Shares Hit Record Low Amid Capital Raise and Strategic Shifts
  • Evolent Health Bets on AI Leadership Amid Share Price Decline

Category

  • About
  • Advertise
  • Careers
  • Contact
  • Imprint
  • Privacy Policy
  • Terms of Service

© 2023 StocksToday.com

No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing

© 2023 StocksToday.com